Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Gebhart, G; Lamberts, Le; Wana, Z; Garcia, C; Emonts, P; Ameye, L; Stroobants, S; Huizing, M; Aftimos, P; Tol, J; Oyen, W; Vugts, Dj; Hoekstra, Os; Schroder, Cp; van Oordt, Cwmv; Guiot, T; Brouwers, Ah; Awada, A; de Vries, Ege; Flamen, P